Please login to the form below

Not currently logged in
Email:
Password:

mutiple myeloma

This page shows the latest mutiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Mixed cancer news from NICE

Mixed cancer news from NICE

Mixed cancer news from NICE. Agency backs Janssen’ s myeloma drug but denies Bayer’ s Xofigo in prostate cancer. ... The cost-effectiveness agency issued draft guidance giving the green light to Janssen's Velcade in the treatment of certain patients

Latest news

  • NICE denies early use of Janssen’s Velcade NICE denies early use of Janssen’s Velcade

    Janssen's Velcade is not a cost-effective use of NHS resources for the early treatment of multiple myeloma, according to new draft guidance from England's health guidance body. ... The drug is already recommended by NICE for use in combination with an

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics